A tree resin whose plant steroids act on the liver switch governing how cholesterol becomes bile, and damp an inflammatory pathway. Its blood-fat case is directly contested: South Asian research found reductions, the most rigorous Western research found harmful cholesterol rising. Against that unsettled benefit sit reliable costs: allergic rash, digestive complaints, and lowered blood levels of heart medicines. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL-C | < 100 mg/dL; < 70 with established plaque | The primary target, and the marker guggul may move in the wrong direction |
| ApoB | < 80 mg/dL; < 60 with established plaque | Counts every artery-damaging particle, catching risk LDL-C alone misses |
| Total cholesterol | < 200 mg/dL | The endpoint used in the meta-analysis, making results comparable to trial data |
| Triglycerides | < 100 mg/dL | Second lipid endpoint that responded in the Indian trials |
| HDL-C | > 50 mg/dL men, > 60 mg/dL women | One trial reported it falling on guggul, so it needs watching |
| hs-CRP | < 1.0 mg/L | Tracks the anti-inflammatory effect underlying the joint and skin claims |
| TSH | 0.5–2.0 mIU/L | Detects the thyroid shift, which is symptomless until advanced |
| Free T4 | 1.0–1.5 ng/dL | Distinguishes a genuine thyroid change from pituitary noise on the TSH result |
| ALT and AST | < 25 U/L men, < 20 U/L women | Confirms the resin is not stressing the liver during exposure |
| Vitamin D, 25-hydroxy | 40–60 ng/mL | No established guggul-specific target; a general fat-soluble status check against the individual's own baseline |
Cadence: Baseline before the first dose. Lipid panel and liver enzymes repeated at 8 weeks; thyroid function likewise at 8 weeks where thyroid disease or replacement therapy is present; every 3 to 6 months if the decision is to continue.